Current epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) treatment, including gefitinib and afatinib, are highly effective to extracranial lung cancer patients with specific EGFR mutations [1]. The gene discussed is EGFR; the disease is lung cancer.